Ipsen (OTCPK:IPSEY) subsidiary Clementia Pharmaceuticals and Blueprint Medicines (NASDAQ:BPMC) have entered
into an exclusive, worldwide license agreement for the development and
commercialization of BLU-782, an oral, highly selective investigational
ALK2 inhibitor being developed for the treatment of fibrodysplasia
ossificans progressiva (FOP).
Subject to the terms of the license agreement,
Blueprint Medicines will be eligible to receive up to $535M in upfront,
milestone and other payments, including an upfront cash payment of $25M
and up to $510M in milestone payments, plus tiered percentage royalties
ranging from the low- to mid-teens.
https://seekingalpha.com/news/3506031-ipsen-licenses-blueprint-medicines-bluminus-782-treatment-fop
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.